3D GLOBAL BIOTECH INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 42.4 TWD | +6.67% |
|
+8.16% | +117.99% |
| Apr. 19 | 3D Global Biotech Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | 3D Global Biotech Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 | CI |
| Sales 2022 | 13.64M 421K | Sales 2023 | 20.63M 637K | Capitalization | 1.09B 33.6M |
|---|---|---|---|---|---|
| Net income 2022 | -67M -2.07M | Net income 2023 | -58M -1.79M | EV / Sales 2022 | 95.7 x |
| Net cash position 2022 | 192M 5.92M | Net cash position 2023 | 156M 4.81M | EV / Sales 2023 | 45.2 x |
| P/E ratio 2022 |
-22
x | P/E ratio 2023 |
-18.8
x | Employees | 33 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 68.74% |
More Fundamentals
* Assessed data
More news
| 1 day | +6.67% | ||
| 1 week | +8.16% | ||
| Current month | +8.16% | ||
| 1 month | +29.07% | ||
| 3 months | +49.30% | ||
| 6 months | +111.47% | ||
| Current year | +117.99% |
1 week
39.00
44.95
1 month
35.9544.95
Current year
18.8044.95
1 year
17.2044.95
3 years
17.2045.45
5 years
17.2076.00
10 years
17.2076.00
| Managers | Title | Age | Since |
|---|---|---|---|
Keng Liang Ou
CEO | Chief Executive Officer | - | 15-01-14 |
Jui Wen Huang
DFI | Director of Finance/CFO | - | 17-04-17 |
Hsu An Pan
CTO | Chief Tech/Sci/R&D Officer | - | 20-01-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ming Hsien Chen
BRD | Director/Board Member | - | 20-11-18 |
Chi Ying Chiu
BRD | Director/Board Member | - | 20-11-18 |
Keng Liang Ou
CEO | Chief Executive Officer | - | 15-01-14 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-07-05 | 42.4 | +6.67% | 1,120,043 |
| 24-07-04 | 39.75 | +0.13% | 173,352 |
| 24-07-03 | 39.7 | -0.63% | 171,751 |
| 24-07-02 | 39.95 | -0.12% | 322,315 |
| 24-07-01 | 40 | +2.04% | 377,742 |
End-of-day quote Taipei Exchange, July 04, 2024
More quotes
3D Global Biotech Inc a biotechnology company mainly engaged in the development of medical materials for human reconstruction, focusing on the development of high-end medical equipment and biological printing technology. The Company mainly provides hard tissue reconstruction medical materials and soft tissue reconstruction medical materials. The hard tissue reconstruction medical materials mainly provide customized services for dental medical materials, original equipment manufacturer services for customized products of cranial implants, and orthopedics and dental reconstruction medical materials DGRA01: α-Former bone filling materials and the second-level medical equipment product of craniofacial jaw reconstruction medical materials DGRA03: SmileAlign transparent correction system. The soft tissue reconstruction medical materials mainly include bio-ink product DGRC02: 3D Bioture EX water gel stent.
| 1st Jan change | Capi. | |
|---|---|---|
| +117.99% | 87.25M | |
| -5.50% | 181B | |
| -5.79% | 99.52B | |
| -6.59% | 65.82B | |
| -8.38% | 45.21B | |
| +8.42% | 43.85B | |
| +10.10% | 42.17B | |
| +10.97% | 28.75B | |
| +18.89% | 25.39B | |
| -8.39% | 23.5B |
- Stock Market
- Equities
- 6808 Stock
